AstraZeneca Iressa
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca's Iressa (gefitinib) is slated for review by FDA's Oncologic Drugs Advisory Committee Sept. 24. A rolling NDA for use of the epidermal growth factor receptor/tyrosine kinase inhibitor for treatment of non-small cell lung cancer was completed Aug. 5. The NDA contains two Phase II monotherapy studies in approximately 400 patients to support efficacy. Recent data from the Phase III INTACT 1 and 2 mortality trials, which examined Iressa in combination with standard platinum-based chemotherapy, failed to show a benefit in survival or symptom improvement. In announcing the results, the firm indicated that FDA could change the agenda for the Sept. 24 ODAC meeting. AstraZeneca plans to focus future studies on monotherapy use in sequential therapy regimens, with initial studies in the neoadjuvant settin
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.